The disclosure provides genetically engineered microorganisms capable of producing antigen-binding molecules. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from undesirable products towards products, and optionally co-products, of interest. Further, the disclosure enables co-production of useful chemicals from gaseous substrates.

Sized-based detection techniques for detection of bio-nanoparticles are described. Detection nanoparticles and methods of forming the detection nanoparticles that can be utilized in the techniques are described. Detection nanoparticles can include modified bacteriophage that express a linking agent for a specific binding agent. Detection nanoparticles can bind a functional bio-nanoparticle with high specificity through specific binding of one or more entities unique to the functional bio-nanoparticle of interest. A detection nanoparticle can target an entity of a bio-nanoparticle that is relevant to its function, and as such, the methods can provide improvements in detection of complete and functional bio-nanoparticles. Size-based detection regimes can include particle displacement measurement techniques based upon Brownian motion.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).

Methods and apparatuses (e.g., systems, devices, etc.) for delivering a nebulized drug agent in the nasal passages concurrent with the lungs.

Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.

Compositions for use as a vaccine against SARS-CoV-2 infection are disclosed, which comprise either a polypeptide that comprises at least one surge-associated mutation (e.g., deletion) in its amino acid sequence or a nucleic acid (e.g., mRNA) that encodes said polypeptide. Also disclosed are formulations that include these compositions, antibodies or their antigen-biding fragments directed to these polypeptides, methods of making such antibodies, methods of vaccinating subjects against SARS-CoV-2 infection, and methods of selecting an antibody, convalescent plasma, or vaccine against SARS-CoV-2 infection.

Compositions for use as a vaccine against SARS-CoV-2 infection are disclosed, which comprise either a polypeptide that comprises at least one surge-associated mutation (e.g., deletion) in its amino acid sequence or a nucleic acid (e.g., mRNA) that encodes said polypeptide. Also disclosed are formulations that include these compositions, antibodies or their antigen-biding fragments directed to these polypeptides, methods of making such antibodies, methods of vaccinating subjects against SARS-CoV-2 infection, and methods of selecting an antibody, convalescent plasma, or vaccine against SARS-CoV-2 infection.

Disclosed herein is a recombinant antibody exhibiting binding affinity and/or neutralizing activity to porcine epidemic diarrhea virus (PEDV). According to some embodiments of the present disclosure, the PEDV is genotype 1 (G1) or genotype 2b (G2b) PEDV. Also disclosed herein are methods of diagnosing and treating PEDV infection by use of the present recombinant antibody.

Disclosed herein is a recombinant antibody exhibiting binding affinity and/or neutralizing activity to porcine epidemic diarrhea virus (PEDV). According to some embodiments of the present disclosure, the PEDV is genotype 1 (G1) or genotype 2b (G2b) PEDV. Also disclosed herein are methods of diagnosing and treating PEDV infection by use of the present recombinant antibody.